Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR

Abstract

To assess the prevalence and prognostic value of myeloid differentiation factor 88 (MYd88) expression and mutational status in diffuse large B cell lymphoma (dlBcl), a total cohort of 100 patients with dlBcl were studied using immunohistochemistry (iHc) and droplet digital polymerase chain reaction (ddPcr), and the association between MYd88 expression and clinicopathological parameters was analyzed. overall, the positive expression rate of MYd88 protein was 38% and the gene mutation rate was 29%. The positive expression and mutation rates were the highest in the primary central nervous system lymphomas (58.33 and 66.67%, respectively). The coincidence rate of the results of MYd88 expression between iHc and ddPcr results was 73% (73/100). univariate survival analysis showed that age (≥60 years old), high neutrophil/lymphocyte count ratio, low lymphocyte count, c-Myc ≥40%, positive MYd88 protein expression, and gene mutation were associated with poorer prognosis rates. Multivariate survival analysis revealed that MYd88 expression was an independent prognostic factor affecting overall survival. in conclusion, the results of this study demonstrated that MYd88 mutation was a valuable index to evaluate the prognosis of dlBcl. ddPcr can be used as a method for detecting MYd88 mutations, although it was not completely consistent with the results of iHc.

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice

“…Further studies confirmed such remarkable site-specific occurrence of MYD88 mutation [55,56]. Gastrointestinal DLBCL <5% [60] 11% [40] Absent [40] Primary Bone DLBCL Absent [60] Absent [60] Absent [60] Thyroid gland DLBCL Absent [60] Absent [60] Absent [60] Head and Neck DLBCL Unknown [60] 3.17% (small sample size) [61] Unknown [60] Primary Pulmonary DLBCL Data not available Data not available Data not available…”

Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology

“…Similarly, MAPK signaling inactivation contributes to a reduced the chance of COVID-19 [38,39]. Prior studies have suggested that elevated pro-inflammatory IL-17 is associated with elevated NOD-like receptor [40,41]. NOD-like receptor, one of the inflammatory components, can increase the expression of interleukin-1β [35].…”

Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study

“…In the study by Niu et al . [ 1 ] the MYD88 expressions in DLBCL were examined by performing immunohistochemical methods to evaluate MYD88 protein expression. Limited research has been performed by immunohistochemical method to detect expression of MYD88 protein.…”

“…The higher Bcl-2 expression was associated with positive MYD88 protein expression in the Niu et al . [ 1 ] study, which might show that Bcl-2 and MYD 88 expression impede apoptosis of tumour cells, encourage its proliferation, augmenting the other oncogenes’ role in lymphoma cells. The progress of lymphoma is accelerated by Bcl-2 protein, and it encourages lymphoma cell resistance to chemotherapy drugs [ 21 ].…”

“…Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is the largest common category of adult lymphoma [ 1 ]. B-cell lymphomas are heterogeneous tumour as regards histomorphology, clinical manifestations, immunophenotyping, and prediction of prognosis [ 2 ].…”